Selection of @entity1 and staging of peritoneal surface XXXX .

@entity1 @entity43 @entity66 @entity5 @entity189 @entity1725 @entity1820 @entity14 @entity298
@entity298 ( @entity298 ) is a common evolution of @entity1820 , and has been traditionally regarded as a @entity66 with short median survival. During the last 20 years, thanks to its favourable oncologic results, a new loco-regional therapeutic approach, combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), has an important development. Due to its significant, but acceptable, morbidity and mortality, and high cost, this comprehensive management plan requires knowledgeable @entity1 selection. Quantitative prognostic indicators are required to assess a @entity1 's eligibility. Large multicenter studies have identified several prognostic factors, which can be used for a better selection of @entity1 who would benefit from the combination of cytoreductive surgery with HIPEC. Indications for treatment of @entity298 with cytoreduction and HIPEC are now validated for several diseases: peritoneal mesothelioma, @entity1725 , @entity298 from the appendix, and @entity14 . Indications are still under discussion for @entity43 . Computed tomography is the best radiological for staging the disease. The extent of @entity298 is, however, difficult to evaluate preoperatively, and precise evaluation is most often performed during surgical exploration. Cytoreductive surgery associated with HIPEC for the treatment of @entity298 should be performed for young @entity1 with limited and resectable @entity189 , in specialized institutions involved in the management of peritoneal surface @entity5 .
